FrancophonIA/ELRC3.0 huggingface dataset:
English: Valproat HEXAL chrono 300 mg Retardtabletten
Estonian: Valproat HEXAL chrono 300 mg Retardtabletten 300 mg
English: Ergenyl Chronosphere 1000 mg Retardgranulat prolonged-release granules
Estonian: Ergenyl Chronosphere 1000 mg Retardgranulat
English: Convulex 300 mgFilmtabletten film-coated tablet
Estonian: Convulex 300 mgFilmtabletten
English: prolonged -release granules
Estonian: Toimeainet prolongeeritult vabastavad graanulid
English: D-39116 Magdeburg Germany espa-valept 300 mg retard 300 mg esparma GmbH Seepark 7
Estonian: D-39116 Magdeburg Saksamaa espa-valept 300 mg retard 300 mg esparma GmbH Seepark 7
English: D-22335, Hamburg Germany
Estonian: D-22335, Hamburg Saksamaa
English: EPILIM 500 ENTERIC COATED TABLETS
Estonian: EPILIM 500 ENTERIC COATED TABLETS 500mg
English: 500 MG/ SACHET modified-release granules
Estonian: 500 MG/ SACHET
English: 250 MG/ SACHET modified-release granules
Estonian: 250 MG/ SACHET
English: Ratiopharm GmbH Graf-Arco-Str. 3 89079 Ulm Germany
Estonian: Ratiopharm GmbH Graf-Arco-Str. 3 89079 Ulm Saksamaa
English: 22335 Hamburg Germany
Estonian: 22335 Hamburg Saksamaa
English: AWD.pharma GmbH & Co. KG Wasastr.
Estonian: AWD.pharma GmbH & Co.
English: Convulex 150 mg gastroresistant capsules, soft gastro-resistant capsule, soft
Estonian: Convulex 150 mg gastroresistant capsules, soft
English: 300 mg/ml oral drops
Estonian: 300 mg / 1 ml of drops
English: betapharm Arzneimittel GmbH Kobelweg 95
Estonian: betapharm Arzneimittel GmbH
English: 57.64 mg/ml syrup
Estonian: 57.64 mg/ml
English: Poland ratiopharm GmbH Graf-Arco-Strasse 3 Ulm89079
Estonian: Poola ratiopharm GmbH Graf-Arco-Strasse 3 Ulm89079
English: Valproat HEXAL chrono 500 mg Retardtabletten
Estonian: Valproat HEXAL chrono 500 mg Retardtabletten 500 mg
English: Convulex 500 mg gastroresistant capsules, soft gastro-resistant capsule, soft
Estonian: Convulex 500 mg gastroresistant capsules, soft
English: Depakine 300 mgFilmtabletten film-coated tablet
Estonian: Depakine 300 mgFilmtabletten
English: D-39116 Magdeburg Germany espa-valept 300mg esparma GmbH Seepark 7
Estonian: D-39116 Magdeburg Saksamaa espa-valept 300mg esparma GmbH Seepark 7
English: Poland ratiopharm GmbH Graf-Arco-Strasse 3 Ulm 89079
Estonian: Poola ratiopharm GmbH Graf-Arco-Strasse 3 Ulm 89079
English: Depakine Chronosphere 100 mg modified-release granules
Estonian: DEPAKINE CHRONOSPHERE 100 MG Granulado de liberación modificada
English: 300 mg/5 ml syrup
Estonian: 300 mg/5 ml
English: Ratiopharm GmbH Graf-Arco-Strasse 3 89079 Ulm Germany
Estonian: Ratiopharm GmbH Graf-Arco-Strasse 3 89079 Ulm Saksamaa
English: Depakine Chronosphere 250 mg modified-release granules
Estonian: DEPAKINE CHRONOSPHERE 250 mg granulado de liberación modificada
English: Czech Republic ratiopharm GmbH Graf-Arco-Straße 3 89079 Ulm Germany
Estonian: Tsehhi ratiopharm GmbH Graf-Arco-Straße 3 89079 Ulm Saksamaa
English: Depakine Chronosphere 50350 mg/DosisRetardgranulat prolonged-release granules
Estonian: Depakine Chronosphere 50-350 mg/DosisRetardgranulat
English: Depakine Chronosphere 750 mg modified-release granules
Estonian: DEPAKINE CHRONOSPHERE 750 MG Granulado de liberación modificada
English: Ergenyl Chronosphere 750 mg Retardgranulat prolonged-release granules
Estonian: Ergenyl Chronosphere 750 mg Retardgranulat
English: Valproat-CT 600 mg Filmtabletten neuraxpharm Arzneimittel GmbH u. Co.KG Elisabeth-Selbert-Str. 23 D-40764 Langenfeld Germany
Estonian: Valproat-CT 600 mg Filmtabletten neuraxpharm Arzneimittel GmbH u. Co.KG Elisabeth-Selbert-Str. 23 D-40764 Langenfeld Saksamaa
English: Valproic Acid ER-APC 300 300 mg
Estonian: Valproic Acid ER-APC
English: Depakine Chronosphere 1000 mg - Retardgranulat in Beuteln prolonged-release granules
Estonian: Depakine Chronosphere 1000 mg - Retardgranulat in Beuteln
English: DEPAKINE CHRONOSPHERE 500 MG Granulado de liberación modificada modified-release granules
Estonian: DEPAKINE CHRONOSPHERE 500 MG Granulado de liberación modificada
English: D-22335 Hamburg Germany
Estonian: D-22335 Hamburg Saksamaa
English: Ergenyl Chronosphere 100 mg Retardgranulat prolonged-release granules
Estonian: Ergenyl Chronosphere 100 mg Retardgranulat
English: gastro-resistant capsule Oral Use
Estonian: Gastro-resistentne pehmekapsel
English: Depakine Chronosphere 50200 mg/DosisRetardgranulat prolonged-release granules
Estonian: Depakine Chronosphere 50-200 mg/DosisRetardgranulat
English: 200 mg/5 ml syrup
Estonian: 200 mg/5 ml
English: Depakine Chronosphere 750 mg - Retardgranulat in Beuteln prolonged-release granules
Estonian: Depakine Chronosphere 750 mg - Retardgranulat in Beuteln
English: Ergenyl Chronosphere 250 mg Retardgranulat prolonged-release granules
Estonian: Ergenyl Chronosphere 250 mg Retardgranulat
English: Valproat-neuraxpharm chrono 300 mg neuraxpharm Arzneimittel GmbH u. Co.KG Elisabeth-Selbert-Str. 23 D-40764 Langenfeld Germany
Estonian: Valproat-neuraxpharm chrono 300 mg neuraxpharm Arzneimittel GmbH u. Co.KG Elisabeth-Selbert-Str. 23 D-40764 Langenfeld Saksamaa
English: 200 mg/ml oral solution
Estonian: DEPAKINE solución oral 200 mg/ml
English: 50 MG/ SACHET modified-release granules
Estonian: 50 MG/ SACHET
English: AT-1160 Wien
Estonian: AT-1160 Wien AUSTRIA
English: Depakine Chronosphere 100 mg - Retardgranulat in Beuteln prolonged-release granules
Estonian: Depakine Chronosphere 100 mg - Retardgranulat in Beuteln
English: Depakine Chronosphere 250 mg - Retardgranulat in Beuteln prolonged-release granules
Estonian: Depakine Chronosphere 250 mg - Retardgranulat in Beuteln
English: 200mg/5ml syrup
Estonian: 200mg/5ml
English: Valproinsäure Valeant 600 600 mg ratiopharm GmbH D-89070 Ulm Germany
Estonian: Valproinsäure Valeant ratiopharm GmbH D-89070 Ulm Saksamaa
English: Empreendimento Lagoas Park, Edifício 7 - 3º
Estonian: Empreendimento Lagoas Park, Edifício 7 - 3º 2740-299 Porto Salvo Portugal
English: Ergenyl Chronosphere 50 mg Retardgranulat prolonged-release granules
Estonian: Ergenyl Chronosphere 50 mg Retardgranulat
English: VALPROATE SODIUM SANDOZ 500MG
Estonian: VALPROATE SODIUM SANDOZ 500MG 500mg
English: VALPROATE SODIUM SANDOZ 300MG
Estonian: VALPROATE SODIUM SANDOZ 300MG 300mg
English: Ergenyl Chronosphere 500 mg Retardgranulat prolonged-release granules
Estonian: Ergenyl Chronosphere 500 mg Retardgranulat
English: Depakine Chronosphere 50 mg - Retardgranulat in Beuteln prolonged-release granules
Estonian: Depakine Chronosphere 50 mg - Retardgranulat in Beuteln
English: Depakine Chronosphere 500 mg - Retardgranulat in Beuteln prolonged-release granules
Estonian: Depakine Chronosphere 500 mg - Retardgranulat in Beuteln
English: DEPAKINE CHRONO 300mg tablet
Estonian: DEPAKINE CHRONO 300mg
English: 333,30 mg + 145,14 mg prolonged-release granules
Estonian: 333,30 mg + 145,14 mg
English: 100 MG/ SACHET modified-release granules
Estonian: 100 MG/ SACHET
English: MICROPAKINE LP
Estonian: MICROPAKINE LP 100 mg
English: 100 mg/ml syrup
Estonian: 100 mg/ml
English: Convulsofin Tabletten tablet
Estonian: Õhukese polümeerikattega tablett Suukaudne
English: Depakine tablet
Estonian: Depakine Zuur
English: ORFIRIL LONG 150 mg 150 mg prolonged-release capsule
Estonian: ORFIRIL LONG 150 mg 150 mg
English: Valproinsäure Valeant 300 300 mg
Estonian: Ácido Valpróico Generis 300 mg
English: Valproat-neuraxpharm 300 300 mg neuraxpharm Arzneimittel GmbH u. Co.KG Elisabeth-Selbert-Str. 23 D-40764 Langenfeld Germany
Estonian: Valproat-neuraxpharm neuraxpharm Arzneimittel GmbH u. Co.KG Elisabeth-Selbert-Str. 23 D-40764 Langenfeld Saksamaa
English: 250 mg/dose prolonged-release granules
Estonian: 250 mg/dose
English: DEPAKINE CHRONO 500mg tablet
Estonian: DEPAKINE CHRONO 500mg
English: Natriumvalproat Desitin retard 150 mg prolonged-release capsule
Estonian: Natriumvalproat Desitin retard 150 mg
English: VALPROATE DE SODIUM RATIOPHARM L.P.
Estonian: RATIOPHARM L.P.
English: DEPAKINE solución oral
Estonian: Depakine suikervrije stroop
English: Czech Republic
Estonian: Tsehhi
English: 1000 mg/dose prolonged-release granules
Estonian: 1000 mg/dose
English: 300 mg (199,8 mg/ 87 mg) modified-release tablet Oral Use
Estonian: 300 mg (199,8 mg/ 87 mg)
English: Orfiril CR 1000 mg modified-release granules
Estonian: Orfiril CR 1000 mg
English: SANOFI AVENTIS FRANCE 1-13, boulevard Romain Rolland
Estonian: 1-13, boulevard Romain Rolland
English: List of the names, pharmaceutical form(s), strength(s) of the medicinal product(s), route(s) of administration, applicant(s) in the Member States
Estonian: Ravimite nimetuste, ravimvormide, tugevuste, manustamisviiside taotlejate loetelu liikmesriikides
English: Content (concentration)
Estonian: Ravimvorm Manustamisviis Pakendi sisu (kontsentratsioon)
English: 3.5 hours
Estonian: 3,5 tundi
English: • if you are a child (less than 18 years of age), this medicine is not appropriate for you.
Estonian: • Kui te olete laps (alla 18aastane) ei ole see ravim teile sobiv.
English: Currently available data are described in sections 5.1 and 5.2.
Estonian: Antud hetkel teadaolevad andmed on esitatud lõikudes 5.1 ja 5.2.
English: *Superiority p-value.
Estonian: *Ülekaalukas p-value.
English: Compartment syndrome a, b
Estonian: Kompartmendi sündroom a, b
English: Mortality among these patients was nil.
Estonian: Suremus nende patsientide hulgas oli null.
English: INR increased d
Estonian: INR tõus d
English: The majority of these cases were non-fatal.
Estonian: Enamik nendest juhtudest ei olnud letaalsed.
English: 30 day Composite MACE
Estonian: 30 päeva komposiit MACE
English: • before the start of the injection or infusion, the doctor will tell you about the signs of allergic reaction.
Estonian: • enne süstimise või infusiooni algust informeerib arst teid allergilise reaktsiooni nähtudest.
English: This may, rarely, result in a stroke or be fatal.
Estonian: See võib harvadel juhtudel põhjustada insulti või olla isegi surmav.
English: • Brief information on preparation and administration instructions.
Estonian: • Lühike teave lahuse valmistamise ja manustamise kohta.
English: Ischaemic Components All cause death
Estonian: Isheemilised komponendid Kõik surmapõhjused
English: Date of first authorisation: 20.09.2004 Date of latest renewal: 23.06.2014
Estonian: Müügiloa esmase väljastamise kuupäev: 20.09.2004 Müügiloa viimase uuendamise kuupäev: 23.06.2014
English: Relative Risk [95% CI]
Estonian: Suhteline risk [95% CI]
English: Comparison of the single and repeated dose studies revealed that toxicity was related primarily to duration of exposure.
Estonian: Ühekordse ja korduva manustamisega uuringute tulemuste võrdlemisest ilmnes, et toksilisus oli eelkõige seotud ekspositsiooni kestvusega.
English: There is currently no indication for the use of Angiox in children less than 18 years old and no recommendation on a posology can be made.
Estonian: Praegu puudub Angiox'i kasutus lastel vanuses alla 18 aasta ja soovitusi annustamise kohta ei ole võimalik anda.
English: All the undesirable effects, primary and secondary, resulting from excessive pharmacological activity were reversible.
Estonian: Kõik kõrvaltoimed - nii primaarsed kui ka sekundaarsed -, mis tulenesid ülemäärasest farmakoloogilisest toimest, olid pöörduvad.
English: Justification for not including Braille accepted.
Estonian: Põhjendus Braille' kirja (punktkirja) mitte lisamiseks on aktsepteeritav.
English: Any unused product or waste material should be disposed of in accordance with local requirements.
Estonian: Kasutamata ravimpreparaat või jäätmematerjal tuleb hävitada vastavalt kohalikele nõuetele
English: Do not use Angiox
Estonian: Ärge kasutage Angiox'i
English: Clearance (ml/min/kg)
Estonian: Kliirens (ml/min/kg)
English: • Bleeding and bruising at the puncture site (after PCI treatment) may be painful.
Estonian: • Verejooks ja verevalum punktsiooni kohal (pärast PKI-ravi) võib olla valulik.
English: • Do not use bivalirudin without first diluting it.
Estonian: • Ärge kasutage bivalirudiini enne selle lahjendamist.
English: OUTER CARTON (pack of 10 vials)
Estonian: VÄLISKARP (10-viaaline pakend)
English: • if bleeding occurs (if this happens, treatment with Angiox will be stopped).
Estonian: • kui esineb verejooks (kui see juhtub, katkestatakse Angiox'i manustamine).
English: If you get any of the following, potentially serious, side effects:
Estonian: Kui teil tekib mis tahes järgmine potentsiaalselt tõsine kõrvaltoime:
English: • Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being
Estonian: • kui muudetakse riskijuhtimissüsteemi, eriti kui saadakse uut teavet, mis võib oluliselt mõjutada riski/kasu suhet, või kui saavutatakse oluline (ravimiohutuse või riski
English: If you cannot get access to your doctor go immediately to the Emergency Department of your nearest hospital
Estonian: Kui te ei saa arstiga ühendust, pöörduge koheselt lähima haigla erakorralise meditsiini osakonda
English: This dosing regimen is required to achieve and maintain the plasma concentration required for effective ischaemic protection during PCI.
Estonian: Selline annustamisskeem on vajalik plasmakontsentratsiooni saavutamiseks ja säilitamiseks, mis tagab tõhusa isheemiavastase kaitse PKI ajal.
English: The clinical utility of ACT in neonates and children should be considered with caution considering their developmental haematological state.
Estonian: ACT kasutamise kliinilisse kasulikkusse vastsündinute ja laste puhul tuleb suhtuda ettevaatusega, arvestades nende hematoloogilist arengut.
English: The ACT vs concentration data suggest a trend for a lower concentration response curve for adults as compared to older children (6 years to < 16 years) and younger children (2 years to <6 years), and for older children compared to infants (31 days to <24 months) and neonates (birth to 30 days).
Estonian: ACT vs kontsentratsiooni andmed näitavad täiskasvanutel kontsentratsiooni ja ravivastuse kõvera väiksemat suundumust võrreldes vanemate (6 aastat kuni < 16 aastat) ja nooremate lastega (2 aastat kuni < 6 aastat) ning vanematel lastel võrreldes imikutega (31 päeva kuni < 24 kuud) ja vastsündinutega (sünnist kuni 30 päevani).
English: Angiox should not be used during pregnancy unless the clinical condition of the woman requires treatment with bivalirudin.
Estonian: Angiox'i ei tohi kasutada raseduse ajal, väljaarvatud juhul, kui naise kliiniline seisund vajab ravi bivalirudiiniga.
English: The bioavailability of bivalirudin for intravenous use is complete and immediate.
Estonian: Bivalirudiini biosaadavus intravenoossel manustamisel on täielik ja kohene.
English: Hypersensitivity, including anaphylactic reaction and shock, including reports with fatal outcome
Estonian: Ülitundlikkus, sh anafülaktiline reaktsioon ja šokk, sh teated fataalsest lõpptulemusest
English: • if you have been treated before with medicines similar to Angiox (e.g. lepirudin).
Estonian: • kui teid on varem ravitud Angiox'iga sarnaste ravimitega (nt lepirudiin).
English: The most frequent event was a haematoma <5 cm at puncture site.
Estonian: Kõige sagedasem oli hematoom <5 cm raadiuses punktsioonikohast.
English: • Allergic reactions,- are uncommon (may affect up to 1 in 100 people) and usually not serious but can become severe under some circumstances, and in rare cases may be fatal due to low blood pressure (shock).
Estonian: • Allergilisi reaktsioone esineb aeg-ajalt (võib esineda kuni 1 inimesel 100-st) ja need ei ole tavaliselt rasked, kuid võivad teatud tingimustel muutuda raskeks ja olla harvadel juhtudel fataalsed madala vererõhu (šoki) tõttu.
English: In all clinical studies bleeding data were collected separately from adverse reactions and are summarised in Table 6 together with the bleeding definitions used for each study.
Estonian: Kõikides kliinilistes uuringutes koguti andmeid verejooksu kohta eraldi andmetest ravimi kõrvaltoimete kohta ning nende kokkuvõte on esitatud Tabelis 6 koos iga uuringu raames kasutatud verejooksu definitsioonidega.
English: What Angiox contains
Estonian: Mida Angiox sisaldab
English: The doctor will decide how much Angiox you receive, and will prepare the medicine.
Estonian: Arst otsustab kui palju Angiox'i teile manustatakse ja valmistab ravimi ette.
English: Approximately 66% of patients were pre-treated with unfractionated heparin.
Estonian: Ligikaudu 66% patsientidest said eelnevalt fraktsioneerimata hepariini ravi.
English: Angiox has no or negligible influence on the ability to drive and use machines.
Estonian: Angiox ei mõjuta või mõjutab ebaoluliselt autojuhtimise ja masinate käsitsemise võimet.
English: The educational materials will be used in all member states for both initial training and re-education in the event of reports of bolus only dosing without subsequent infusion.
Estonian: Hariduslikku materjali kasutatakse kõigis liikmesriikides nii esialgseks koolituseks kui ka korduvate koolituste läbiviimiseks, kui saadakse teateid ainult boolusannuse kasutamise kohta sellele järgneva infusioonita.
English: In the case of shock, the current medical standards for shock treatment should be applied.
Estonian: Šoki korral tuleb rakendada tänapäeva meditsiinilistele standarditele vastavat šokiravi.
English: Haematoma, Hypotension
Estonian: Hematoom, hüpotensioon
English: Do not use this medicine after the expiry date which is stated on the label and carton after ‘EXP'.
Estonian: Ärge kasutage seda ravimit pärast kõlblikkusaega, mis märgitud sildil ja karbil pärast „Kõlblik kuni”.
English: The corresponding clearance is about 3.4  0.5 ml/min/kg.
Estonian: Sellele vastav kliirens on umbes 3,4 ±0,5 ml/min/kg.
English: No dose adjustment is needed.
Estonian: Annuse kohandamine ei ole vajalik.
English: There was no statistically significant difference in the rates of stent thrombosis between treatment arms at 30 days (p=0.3257) and 1 year (p=0.7754).
Estonian: Statistiliselt olulisi erinevusi stendi tromboosi näitajate osas uuringuharude vahel vahemikus 30 päeva (p=0,3257) ja 1 aasta (p=0,7754) ei esinenud.
English: About 20% of bivalirudin is excreted unchanged in the urine.
Estonian: Umbes 20% bivalirudiinist eritub muutumatul kujul uriiniga.
English: Bleeding Definitions
Estonian: Verejooksu definitsioonid
English: Animal studies are insufficient with respect to effects on pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).
Estonian: Loomkatsete põhjal ei saa välistada toimet rasedusele, embrüo/loote arengule, sünnitusele või postnataalsele arengule (vt lõik 5.3).
English: Caution should be exercised in patients previously treated with lepirudin who had developed lepirudin antibodies.
Estonian: Ettevaatlik tuleb olla patsientide puhul, kes on varasemalt saanud lepirudiini ja kellel on tekkinud lepirudiini antikehad.
English: Your doctor will decide whether or not this treatment is appropriate for you.
Estonian: Selle üle, kas antud ravim on teile sobiv või mitte otsustab teie arst.
English: If not used immediately, in use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2-8C unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.
Estonian: Kui seda ei tehta, vastutab valmislahuse ja lahjendatud valmislahuse säilitusaja ja säilitustingimuste eest kasutaja ja see ei tohiks temperatuuril 2-8 C üldjuhul olla pikem kui 24 tundi, välja arvatud juhul kui valmislahuse valmistamine/lahjendamine toimus kontrollitud ja valideeritud asepilistes tingimustes.
English: If, after this, you then need percutaneous coronary intervention (PCI) treatment, the dosage will be increased to:
Estonian: Kui te pärast seda vajate perkutaanse koronaarse interventsiooni (PKI) protseduuri, siis suurendatakse annus järgmiselt:
English: Thrombotic (9/110, 8.2%) and major bleeding events (2/110, 1.8%) were observed in the study.
Estonian: Uuringus täheldati tromboosinähte (9/110, 8,2%) ja olulisi veritsemisnähte (2/110, 1,8%).
English: Bleeding is more likely to occur when Angiox is used in combination with other anticoagulant or antithrombotic medicines (see section 2 ‘Taking other medicines').
Estonian: Verejooks on tõenäolisem, kui Angiox'i kasutatakse koos muude antikoagulantide või antitrombootiliste ravimitega (vt lõiku 2 Kasutamine koos teiste ravimitega).
English: Solutions containing particulate matter should not be used.
Estonian: Osakesi sisaldavat lahust ei tohi kasutada.
English: Other frequently reported adverse events were decreased pedal pulse, catheter site haemorrhage, abnormal pulse, and nausea (8.2%, 7.3%, 6.4% and 5.5%, respectively).
Estonian: Muud sageli esinenud kõrvaltoimed olid jalaarteri pulsi aeglustumine, verejooks kateetri sisestamiskohal, ebanormaalne pulss ja iiveldus (vastavalt 8,2%, 7,3%, 6,4% ja 5,5%).
English: Approximately 77% of patients had recurrent ischaemia, approximately 70% had dynamic ECG changes or elevated cardiac biomarkers, approximately 28% had diabetes and approximately 99% of patients underwent angiography within 72 hours.
Estonian: Ligemale 77%-l patsientidest oli tegemist korduva isheemiaga, 70%-l täheldati dünaamilisi muutusi EKG-s või kardiaalsete biomarkerite sisalduse suurenemist, 28%-l oli tegemist diabeediga ning umbes 99%-l patsientidest teostati 72 tunni vältel angiograafia.
English: Thus, bivalirudin initially acts as a complete non-competitive inhibitor of thrombin, but transitions over time to become a competitive inhibitor enabling initially inhibited thrombin molecules to interact with other clotting substrates and to coagulation if required.
Estonian: Seega toimib bivalirudiin algselt kui trombiini täielik mittekonkureeriv inhibiitor, ent muutub aja jooksul konkureerivaks inhibiitoriks, võimaldades algselt inhibeeritud trombiini molekulidel vajadusel reageerida teiste hüübimissubstraatide toimele või hüübimise protsessile.
English: Half-life (minutes)
Estonian: Poolväärtusaeg (minutit)
English: Undesirable effects that resulted from prolonged physiological stress in response to a non-homeostatic state of coagulation were not seen after short exposure comparable to that in clinical use, even at much higher doses.
Estonian: Ebasoovitavaid toimeid, mis tulenesid pikaaegsest füsioloogilisest stressist vastusena vere mittehomeostaatilisele hüübivusseisundile, ei täheldatud lühiaegse ekspositsiooni korral, mis vastab kliinilisele kasutamisele, seda isegi oluliselt suuremate annuste korral.
English: Pharmacotherapeutic group: antithrombotic agents, Direct thrombin inhibitors, ATC code: B01AE06.
Estonian: Farmakoterapeutiline rühm: tromboosivastased ained, otsesed trombiini inhibiitorid; ATC kood: B01AE06.
English: The use of the Angiox dosing card is recommended as a quick reference guide.
Estonian: Angiox'i annustamiskaardi kasutamine on soovitatav vaid kiire referentsjuhisena.
English: • Reperfusion injury (no or slow reflow): impaired flow in the heart arteries after they have been reopened
Estonian: • reperfusiooni kahjustus (tagasivoolu puudumine või aeglustumine): südamearterite voolu vähenemine pärast nende avamist.
English: Bivalirudin is intended for short-term administration and therefore no data on the long-term carcinogenic potential of bivalirudin are available.
Estonian: Bivalirudiin on mõeldud lühiaegseks kasutamiseks, seetõttu puuduvad andmed bivalirudiini kartsinogeense potentsiaali kohta kestval kasutamisel.
English: Rarely this may require surgery to repair the blood vessel in the groin (fistula, pseudoaneurysm) (may affect up to 1 in 1,000 people).
Estonian: See võib vajada harva operatsiooni niudepiirkonna veresoone ravimiseks (fistul, pseudoaneurüsm) (võib esineda kuni 1 inimesel 1000-st).
English: Angiox is intended for intravenous use.
Estonian: Angiox on mõeldud intravenoosseks kasutamiseks.
English: This medicine contains less than 23 mg of sodium per vial, which means that it is essentially “sodiumfree”.
Estonian: See ravim sisaldab vähem kui 23 mg naatriumi viaali kohta, mis tähendab, et see on põhimõtteliselt „naatriumivaba“.
English: WHAT YOU NEED TO KNOW BEFORE YOU USE ANGIOX
Estonian: Mida on vaja teada enne Angiox'i kasutamist